bevacizumab
Showing 1 - 25 of 1,284
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- +2 more
- Onvansertib
- +3 more
- (no location specified)
Oct 24, 2023
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Completed
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
-
Chicago, IllinoisNorthwestern University
Dec 21, 2022
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Withdrawn
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Jun 1, 2023
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Bevacizumab
- +2 more
-
Los Angeles, California
- +17 more
Jan 27, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Recruiting
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Feb 26, 2023
Colorectal Cancer Metastatic Trial in Guangzhou (Dexamethasone, Anisodamine, Oxaliplatin)
Recruiting
- Colorectal Cancer Metastatic
- Dexamethasone
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Feb 3, 2023
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,
Recruiting
- Cervical Adenocarcinoma
- +47 more
- Bevacizumab
- +3 more
-
Phoenix, Arizona
- +3 more
Dec 5, 2022
Hepatocellular Carcinoma Trial in Nanjing, Shanghai (QL1706, Bevacizumab, Oxaliplatin injection)
Not yet recruiting
- Hepatocellular Carcinoma
- QL1706
- +4 more
-
Nanjing, Jiangsu, China
- +1 more
Jul 28, 2023
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +5 more
- Bevacizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 13, 2022
Colorectal Cancer Trial (all trans Retinoic Acid, Atezolizumab, Bevacizumab)
Not yet recruiting
- Colorectal Cancer
- all trans Retinoic Acid
- +2 more
- (no location specified)
Aug 11, 2023
Colorectal Cancer, Peritoneal Metastases Trial in Eindhoven, Rotterdam (Irinotecan, FOLFOX regimen, Bevacizumab)
Recruiting
- Colorectal Cancer
- Peritoneal Metastases
- Irinotecan
- +2 more
-
Eindhoven, Netherlands
- +1 more
Aug 15, 2023
Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)
Recruiting
- Hepatocellular Carcinoma Non-resectable
- Atezolizumab
- +2 more
-
Taoyuan City, TaiwanChang Gung Memorial Hospital at Linkou
Nov 17, 2023
Metastatic Colorectal Cancer Trial in Madison (Liposomal irinotecan, TAS102, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- Liposomal irinotecan
- +2 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
May 2, 2023
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)
Recruiting
- Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine plus Bevacizumab
- Bevacizumab
-
New Orleans, Louisiana
- +3 more
Dec 16, 2022
Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
- Olaparib
- Bevacizumab
-
San Fermo Della Battaglia, Como, Italy
- +1 more
Nov 2, 2023
Metastatic Hepatocellular Carcinoma Trial in Houston (Atezolizumab, Bevacizumab, ADI-PEG 20)
Not yet recruiting
- Metastatic Hepatocellular Carcinoma
- Atezolizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 24, 2023
Trifluridine/Tipiracil Plus Bevacizumab Versus
Completed
- Metastatic Colorectal Adenocarcinoma
- Trifluridine/Tipiracil
- Bevacizumab
-
Changsha, Hunan, ChinaHunan Cancer hospital
May 11, 2023
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma
Active, not recruiting
- Fallopian Tube Endometrioid Adenocarcinoma
- +7 more
- Anetumab Ravtansine
- +2 more
-
Orange, California
- +22 more
Oct 22, 2022
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell
Recruiting
- Locally Advanced Lung Non-Small Cell Carcinoma
- +9 more
- Bevacizumab
- Brigatinib
-
Duarte, California
- +4 more
Aug 17, 2022
Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)
Not yet recruiting
- Glioblastoma
- Bevacizumab
- +2 more
- (no location specified)
Sep 25, 2023
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With
Completed
- Metastatic Colorectal Adenocarcinoma
- Fruquintinib
- +3 more
-
Changsha, Hunan, ChinaHunan Cancer hospital
Sep 2, 2023
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Not yet recruiting
- Metastatic Colon Adenocarcinoma
- +6 more
- Balstilimab
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 17, 2022
Advanced HCC, Other Solid Tumors Trial in Shanghai (KD6001, Tislelizumab, Bevacizumab)
Not yet recruiting
- Advanced HCC
- Other Solid Tumors
- KD6001
- +2 more
-
Shanghai, ChinaZhongshan Hospital
Jun 13, 2023